Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency.
Lynch syndrome
colorectal cancer
deficient mismatch repair
immunotherapy
microsatellite instability
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Mar 2021
08 Mar 2021
Historique:
received:
09
02
2021
revised:
02
03
2021
accepted:
04
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Microsatellite instability (MSI) is a tumor phenotype related to a deficient DNA mismatch repair system (dMMR). This phenotype, observed in 5% of metastatic mCRC but 10-18% of localized CRC, is associated with high tumor mutational burden with highly immunogenic neoantigens. It has emerged as a major predictive biomarker for the efficacy of ICIs. In this review, we will present a comprehensive overview of the literature concerning the efficacy of ICIs in MSI/dMMR mCRC, with a focus on new developments in first-line metastatic setting. Then, we will present current and future challenges of immuno-oncology for patients with MSI/dMMR metastatic CRC.
Identifiants
pubmed: 33800202
pii: cancers13051149
doi: 10.3390/cancers13051149
pmc: PMC7962453
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Natl Cancer Inst. 2021 Feb 1;113(2):208-211
pubmed: 32294214
Fam Cancer. 2018 Jan;17(1):91-100
pubmed: 28616688
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Oncologist. 2019 Nov;24(11):1453-1461
pubmed: 31147488
Cancer Immunol Res. 2018 Dec;6(12):1459-1471
pubmed: 30209062
Fam Cancer. 2013 Mar;12(1):27-33
pubmed: 22987205
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33579738
J Clin Oncol. 2019 Mar 10;37(8):647-657
pubmed: 30702970
Ann Oncol. 2019 Sep 1;30(9):1466-1471
pubmed: 31268130
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922790
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Science. 2019 May 3;364(6439):485-491
pubmed: 31048490
JAMA Oncol. 2019 Apr 1;5(4):551-555
pubmed: 30452494
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Clin Cancer Res. 2017 Jan 1;23(1):104-115
pubmed: 27354468
J Clin Oncol. 2020 Sep 20;38(27):3088-3094
pubmed: 32491962
Cancer Res. 2015 Sep 1;75(17):3446-55
pubmed: 26060019
Oncologist. 2020 Jun;25(6):481-487
pubmed: 31967692
JCO Precis Oncol. 2019;3:
pubmed: 31008436
J Clin Oncol. 2015 Dec 10;33(35):4176-87
pubmed: 26527776
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33148693
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
Cancer Cell. 2019 Jul 8;36(1):35-50.e9
pubmed: 31287991
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Pharmacol Ther. 2015 Mar;147:22-31
pubmed: 25444759
Eur J Cancer. 2017 Nov;86:266-274
pubmed: 29055842
J Immunother Cancer. 2016 Dec 20;4:84
pubmed: 28018599
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
J Clin Oncol. 2019 May 10;37(14):1217-1227
pubmed: 30865548
Int J Cancer. 2020 Jul 1;147(1):285-296
pubmed: 31970760
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Cancer Res. 2017 Mar 1;77(5):1051-1059
pubmed: 28209610
Oncologist. 2019 Nov;24(11):1416-1419
pubmed: 31444293
Eur J Cancer. 2021 Feb;144:9-16
pubmed: 33316636
Clin Colorectal Cancer. 2020 Jun;19(2):137-140
pubmed: 32146081
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301